Tag:

Amgen

Latest Headlines

Latest Headlines

Amgen builds case for bigger Kyprolis market with impressive second-line data

Amgen put out the word Monday that adding Kyprolis to combo therapy with Celgene's Revlimid beat out the Revlimid combo alone in melanoma patients who had relapsed.

Express Scripts hits Amgen, Zogenix as it punts another 25 drugs

Express Scripts has struck again. The pharmacy benefits manager is barring another 25 drugs, including some aging heavyweights like Amgen's anemia drugs Aranesp and Epogen, and newer meds such as the controversial painkiller Zohydro, made by Zogenix.

Amgen preps for swift FDA review as Kyprolis/Revlimid combo stymies myeloma

Amgen put out the word Monday morning that Kyprolis--provided in a combo package with Celgene's Revlimid--beat out Revlimid alone in a head-to-head Phase III study for multiple myeloma, hitting the primary endpoint and offering the Big Biotech a shot at expanding its franchise for the drug at a critical moment in the company's history.

Manufacturing takes it on the chin in Amgen cuts

Amgen is cutting up to 2,900 jobs, and the ax-wielding will fall heavily on manufacturing and R&D sites in Colorado and Washington, whose futures were already dim.

Amgen makes deep job cuts to position itself for post-Enbrel world

When California biotech Amgen picked up Onyx Pharmaceuticals a year ago for $10.4 billion to get its hands on the multiple myeloma drug Kyprolis, investors were wondering what the future would hold for the world's largest biotech. CEO Robert Bradway at least partially answered that question Tuesday saying the company would ax 15% of its workforce.

UPDATED: Amgen axing up to 2,900 staffers, shuttering R&D campus in revamp

Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.

FDA opens the door for a Novartis biosimilar of Amgen's Neupogen

The FDA accepted Novartis' application to sell a knockoff of Amgen's biological treatment Neupogen, making the company a pioneer among those looking to capitalize on a soon-to-come U.S. market for biosimilars that is expected to explode.

Amgen's kidney dialysis drug clears its first Phase III hurdle

Amgen's in-development treatment for patients on kidney dialysis met its primary and secondary goals in a late-stage trial, step one in the drug's three-part Phase III program.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

Amgen scores FDA's 'breakthrough' nod for prospective leukemia therapy

Amgen nabbed a breakthrough designation for its mid-stage blood cancer drug blinatumomab.